First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
Background Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC. Methods We randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD-L1 tumor-expression level of 1% or more to receive nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight once every 2 weeks) or platinum-based chemotherapy (administered once every 3 weeks for up to six cycles). Patients receiving chemotherapy could cross over to receive nivolumab at the time of disease progression. The primary end point was progression-free survival, as assessed by means of blinded independent central review, among patients with a PD-L1 expression level of 5% or more. Results Among the 423 patients with a PD-L1 expression level of 5% or more, the median progression-free survival was 4.2 months with nivolumab versus 5.9 months with chemotherapy (hazard ratio for disease progression or death, 1.15; 95% confidence interval [CI], 0.91 to 1.45; P=0.25), and the median overall survival was 14.4 months versus 13.2 months (hazard ratio for death, 1.02; 95% CI, 0.80 to 1.30). A total of 128 of 212 patients (60%) in the chemotherapy group received nivolumab as subsequent therapy. Treatment-related adverse events of any grade occurred in 71% of the patients who received nivolumab and in 92% of those who received chemotherapy. Treatment-related adverse events of grade 3 or 4 occurred in 18% of the patients who received nivolumab and in 51% of those who received chemotherapy. Conclusions Nivolumab was not associated with significantly longer progression-free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD-L1 expression level of 5% or more. Overall survival was similar between groups. Nivolumab had a favorable safety profile, as compared with chemotherapy, with no new or unexpected safety signals. (Funded by Bristol-Myers Squibb and others; CheckMate 026 ClinicalTrials.gov number, NCT02041533.).
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:376 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 376(2017), 25, Seite 2415 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
David P Carbone [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: | |
|---|---|
| Themen: |
Allografts |
| RVK: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1995100838 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1995100838 | ||
| 003 | DE-627 | ||
| 005 | 20230519014415.0 | ||
| 007 | tu | ||
| 008 | 170721s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20170721 |
| 035 | |a (DE-627)OLC1995100838 | ||
| 035 | |a (DE-599)GBVOLC1995100838 | ||
| 035 | |a (PRQ)p645-53c451bbda4338a23f07fe3880bba35b723f43264125d3953f983a11045982b10 | ||
| 035 | |a (KEY)0171808820170000376002502415firstlinenivolumabinstageivorrecurrentnonsmallcell | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-101 |
| 084 | |a XA 10000 |q AVZ |2 rvk | ||
| 084 | |a 44.60 |2 bkl | ||
| 084 | |a 44.00 |2 bkl | ||
| 100 | 0 | |a David P Carbone |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Background Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC. Methods We randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD-L1 tumor-expression level of 1% or more to receive nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight once every 2 weeks) or platinum-based chemotherapy (administered once every 3 weeks for up to six cycles). Patients receiving chemotherapy could cross over to receive nivolumab at the time of disease progression. The primary end point was progression-free survival, as assessed by means of blinded independent central review, among patients with a PD-L1 expression level of 5% or more. Results Among the 423 patients with a PD-L1 expression level of 5% or more, the median progression-free survival was 4.2 months with nivolumab versus 5.9 months with chemotherapy (hazard ratio for disease progression or death, 1.15; 95% confidence interval [CI], 0.91 to 1.45; P=0.25), and the median overall survival was 14.4 months versus 13.2 months (hazard ratio for death, 1.02; 95% CI, 0.80 to 1.30). A total of 128 of 212 patients (60%) in the chemotherapy group received nivolumab as subsequent therapy. Treatment-related adverse events of any grade occurred in 71% of the patients who received nivolumab and in 92% of those who received chemotherapy. Treatment-related adverse events of grade 3 or 4 occurred in 18% of the patients who received nivolumab and in 51% of those who received chemotherapy. Conclusions Nivolumab was not associated with significantly longer progression-free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD-L1 expression level of 5% or more. Overall survival was similar between groups. Nivolumab had a favorable safety profile, as compared with chemotherapy, with no new or unexpected safety signals. (Funded by Bristol-Myers Squibb and others; CheckMate 026 ClinicalTrials.gov number, NCT02041533.) | ||
| 650 | 4 | |a Cell survival | |
| 650 | 4 | |a Death | |
| 650 | 4 | |a Apoptosis | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a PD-L1 protein | |
| 650 | 4 | |a Survival | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Clinical trials | |
| 650 | 4 | |a Metastasis | |
| 650 | 4 | |a Cancer therapies | |
| 650 | 4 | |a Body weight | |
| 650 | 4 | |a Lung | |
| 650 | 4 | |a Allografts | |
| 650 | 4 | |a Platinum | |
| 650 | 4 | |a Mutation | |
| 650 | 4 | |a Ligands | |
| 650 | 4 | |a Lung cancer | |
| 700 | 0 | |a Martin Reck |4 oth | |
| 700 | 0 | |a Luis Paz-Ares |4 oth | |
| 700 | 0 | |a Benjamin Creelan |4 oth | |
| 700 | 0 | |a Leora Horn |4 oth | |
| 700 | 0 | |a Martin Steins |4 oth | |
| 700 | 0 | |a Enriqueta Felip |4 oth | |
| 700 | 0 | |a Michel M van den Heuvel |4 oth | |
| 700 | 0 | |a Tudor-Eliade Ciuleanu |4 oth | |
| 700 | 0 | |a Firas Badin |4 oth | |
| 700 | 0 | |a Neal Ready |4 oth | |
| 700 | 0 | |a T Jeroen N Hiltermann |4 oth | |
| 700 | 0 | |a Suresh Nair |4 oth | |
| 700 | 0 | |a Rosalyn Juergens |4 oth | |
| 700 | 0 | |a Solange Peters |4 oth | |
| 700 | 0 | |a Elisa Minenza |4 oth | |
| 700 | 0 | |a John M Wrangle |4 oth | |
| 700 | 0 | |a Delvys Rodriguez-Abreu |4 oth | |
| 700 | 0 | |a Hossein Borghaei |4 oth | |
| 700 | 0 | |a George R Blumenschein Jr |4 oth | |
| 700 | 0 | |a Liza C Villaruz |4 oth | |
| 700 | 0 | |a Libor Havel |4 oth | |
| 700 | 0 | |a Jana Krejci |4 oth | |
| 700 | 0 | |a Jesus Corral Jaime |4 oth | |
| 700 | 0 | |a Han Chang |4 oth | |
| 700 | 0 | |a William J Geese |4 oth | |
| 700 | 0 | |a Prabhu Bhagavatheeswaran |4 oth | |
| 700 | 0 | |a Allen C Chen |4 oth | |
| 700 | 0 | |a Mark A Socinski |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d Waltham, Mass. : MMS, 1928 |g 376(2017), 25, Seite 2415 |w (DE-627)129495220 |w (DE-600)207154-X |w (DE-576)014893169 |x 0028-4793 |7 nnns |
| 773 | 1 | 8 | |g volume:376 |g year:2017 |g number:25 |g pages:2415 |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1912254379 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_168 | ||
| 912 | |a GBV_ILN_183 | ||
| 912 | |a GBV_ILN_290 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2219 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_2424 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4256 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4310 | ||
| 912 | |a GBV_ILN_4315 | ||
| 912 | |a GBV_ILN_4320 | ||
| 912 | |a GBV_ILN_4323 | ||
| 936 | r | v | |a XA 10000 |
| 936 | b | k | |a 44.60 |q AVZ |
| 936 | b | k | |a 44.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 376 |j 2017 |e 25 |h 2415 | ||